The study has not yet been published. But MindBioโs CEO Justin Hanka recently released the top-line results on his LinkedIn, eager to show that his company was โin front of the curve in microdosing research.โ He called it โthe most vigorous placebo controlled trial ever performed in microdosing.โ It found that patients dosed with a small amount of LSD (ranging from 4 to 20ฮผg, or micrograms, well below the threshold of a mind-blowing hallucinogenic dose) showed observable upticks in feelings of well-being, but worse MADRS scores, compared to patients given a placebo in the form of a caffeine pill. (Because patients in psychedelic trials typically expect some kind of mind-altering effect, studies are often blinded using so-called โactive placebos,โ like caffeine or methylphenidate, which have their own observable psychoactive properties.)
This means, essentially, that a medium-strength cup of coffee may prove more beneficial in treating major depressive disorder than a tiny dose of acid. Good news for habitual caffeine users, perhaps, but less so for researchers (and biopharma startups) counting on the efficacy of psychedelic microdosing.
โ
Well given I drink multiple cups of coffee, I should be all set. Two 32oz french press made coffee per morning is normal right?